Clinical Trials · NCT03374956

Individualized Obesity Pharmacotherapy

CompletedPhase 3Liraglutide (Approved)
Phase
Phase 3
Recruitment status
Completed
Sponsor
Mayo Clinic
Enrollment
193
Start date
Dec 2017
Locations
1 site, United States
Primary endpoint
Change in Total Body Weight
View Liraglutide compound reference